Compare Funko Inc (FNKO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Novo Nordisk A/S — how do they compare? Funko Inc trades at $6.44 (market cap $363.97M), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 454.2× Funko Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Funko Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Funko Inc for 33 Days and Novo Nordisk A/S for 116 Days on average.
| FNKO | NVO | |
|---|---|---|
Market Cap | $363.97M | $165.31B |
Volume | 1,422,651 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.10 | $63.98 |
52-Week Low | $2.81 | $35.29 |
Typical Hold Time | 33 Days | 116 Days |
Enterprise Value | $584.62M | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Funko (FNKO) trades at $6.50, up 3.01% today, with strong technical momentum showing bullish moving average signals. The company reported mixed Q2 2026 results with revenue growth of 7% to $207.7 million and significant EBITDA improvement, though net income remains negative. Analyst consensus is mixed with 42.9% buy ratings and a $7.58 price target, representing 16.6% upside potential from current levels.
Investment outlook balances improving operational metrics against persistent profitability challenges. The stock offers potential upside based on analyst targets and recent earnings beats, but risks include negative net margins, volatile cash flows, and high debt levels that could pressure shareholder returns in a competitive collectibles market.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
